Prognostic value of inflammatory markers in predicting recurrence-free survival in gastrointestinal stromal tumor patients: A nomogram-based approach

Table 4 Correlation between preoperative platelet/lymphocyte ratio, monocyte/lymphocyte ratio and clinicopathological parameters, n (%)/mean ± SD

Variable	MLR		P value	χ2	PLR		P value	χ2
	< 0.430 (n = 88)	≥ 0.43 (n = 36)			< 181.33 (n = 59)	≥ 181.33 (n = 65)
Gender			0.213	1.549			0.497	0.461
Male	31 (35.2)	17 (47.2)			21 (35.6)	27 (41.5)
Female	57 (64.8)	19 (52.8)			38 (64.4)	38 (58.5)
Age	56.22 ± 13.045	56.14 ± 12.493	0.746	0.105	56.42 ± 55.98	56.98 ± 14.318	0.083	3.059
BMI	22.1 ± 3.687	22.43 ± 3.750	0.852	0.035	22.3 ± 3.967	22.20 ± 3.453	0.262	1.272
Anatomic site of GIST			0.40	4.232			0.953	0.004
Stomach	59 (67.0)	17 (47.2)			36 (61.0)	40 (61.5)
Non-stomach	29 (33.0)	19 (52.8)			23 (39.0)	25 (38.5)
Targeted therapy			0.170	1.879			0.917	0.011
Yes	19 (21.6)	12 (33.3)			15 (25.4)	16 (24.6)
No	69 (78.4)	24 (66.7)			44 (74.6)	49 (75.4)
Tumor size, cm	5.77 ± 3.243	7.74 ± 4.296	0.016	5.928	5.40 ± 2.746	7.19 ± 4.191	0.002	10.508
Size of GIST, cm			0.704	0.144			0.425	0.637
< 5 cm	35 (39.8)	13 (36.1)			25 (42.4)	23 (35.4)
≥ 5 cm	53 (60.2)	23 (63.9)			34 (57.6)	42 (64.6)

PLR: Platelet/lymphocyte ratio; MLR: Monocyte/lymphocyte ratio; GIST: Gastrointestinal stromal tumor; BMI: Body mass index.